A marker group for kidney cancer screening and diagnosis and use thereof

By combining biomarker combinations and mass spectrometry to detect peptide biomarkers in serum, and integrating machine learning algorithms, the problem of insufficient sensitivity and specificity in the early diagnosis and screening of renal cell carcinoma has been solved, achieving efficient diagnosis and early screening of renal cell carcinoma.

CN121186361BActive Publication Date: 2026-04-14长兴固容生物科技有限公司
2 Cites 0 Cited by

Patent Information

Application Number
CN202511736154.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-11-25
Publication Date
2026-04-14
Estimated Expiration
2045-11-25

AI Technical Summary

Technical Problem

Current technologies lack highly sensitive and specific biomarkers for the early diagnosis and screening of renal cell carcinoma. Imaging examinations pose radiation risks and are subject to operational dependence, while liquid biopsy methods suffer from inconsistencies and difficulty in separating viable CTCs.

Method used

A biomarker set, including peptides with specific sequences, is used to detect peptide biomarkers in serum using mass spectrometry. Combined with machine learning algorithms, a diagnostic model is constructed to achieve auxiliary diagnosis and early screening of renal cell carcinoma.

Benefits of technology

It improves the sensitivity and specificity of renal cell carcinoma diagnosis, outperforming existing imaging examinations and multi-gene methylation analysis, while reducing radiation risk and operational dependence, and improving the accuracy of early screening.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a marker group for kidney cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-38.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of kidney cancer.The auxiliary diagnosis result is better than that of one of main current clinical diagnosis schemes for kidney tumors, i.e., imaging examination, and enhanced CT (sensitivity and specificity are 78.67% and 87.88%, respectively).The early screening result is better than that of a high-frequency color Doppler ultrasound instrument (diagnostic sensitivity is 94.87%, and specificity is 80%) applied to the routine examination of the abdomen in a health examination; and multi-gene methylation combined analysis (sensitivity is 62.9%, and specificity is 87.0%).
Need to check novelty before this filing date? Find Prior Art